T. gondii serine protease inhibitor-1 (TgPI-1) modulates dendritic cell maturation

A SOTO; A FARÍAS; M PERRONE SIBILIA; P BERGUER; V MARTÍN; I FENOY; A GOLDMAN

Mar del Plata

Congreso; LXVI Reunión Anual de la Sociedad Argentina de Inmunología 2018; 2018

T. gondii serine protease inhibitor-1 (TgPI-1) modulates dendriticcell maturation We previously showed that treatment with arecombinant T. gondii serine proteaseinhibitor-1 (rTgPI-1) significantly reduced experimental asthma. Co-administrationof rTgPI-1 with the allergen showed an improvement compared with theadministration of rTgPI-1 alone, suggesting that this inhibitor may function asa tolerogenic adjuvant. To further study the mechanism behind TgPI-1 immunomodulatoryactivity, we aimed to study the effect of this protease inhibitor on dendriticcells (DCs). Murine DCs were obtained from BALB/c mice bone-marrow precursors, culturedfor nine days with GM-CSF and then stimulated with LPS. rTgPI-1 (depleted fromendotoxin) was added following three different protocols: rTgPI-1 was added a) duringdifferentiation (day 3-9), b) to immature DCs or c) to DCs matured with LPS. A diminished percentage of CD11+MHCII+ DCs wereobtained when rTgPI-1 was added during differentiation (p